We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Connor Hale and Andrea Park as they discuss medtech's highest paid CEOs.

Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting, and an update on the Horizon Therapudics bidding war. 

To learn more about topics in this episode:
Fierce JPM Week
The top 10 highest-paid medtech CEOs
Fierce Biotech's ASH 2022 Coverage
Fierce Pharma's ASH 2022 Coverage
Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years
Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war
Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?
AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Connor Hale and Andrea Park as they discuss medtech's highest paid CEOs.
Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting, and an update on the Horizon Therapudics bidding war. 
To learn more about topics in this episode:
<ul>
<li><a href="https://www.fiercejpmweek.com/">Fierce JPM Week</a> </li>
<li><a href="https://www.fiercebiotech.com/special-report/top-10-highest-paid-medtech-ceos">The top 10 highest-paid medtech CEOs</a></li>
<li><a href="https://www.fiercebiotech.com/keyword/ash-2022">Fierce Biotech's ASH 2022 Coverage</a></li>
<li><a href="https://www.fiercepharma.com/keyword/ash-2022">Fierce Pharma's ASH 2022 Coverage</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/theranos-sunny-balwani-gets-13-year-fraud-sentence-after-ex-partner-elizabeth-holmes-gets">Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years</a></li>
<li><a href="https://www.fiercepharma.com/pharma/watch-out-amgen-mirati-kicks-kras-showdown-fda-approval-krazati">Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati</a> </li>
<li><a href="https://www.fiercebiotech.com/biotech/fda-advisors-nix-cytokinetics-heart-failure-med-unconvinced-available-data-supported">FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use</a> </li>
<li><a href="https://www.fiercepharma.com/pharma/buyout-horizon-amgen-floats-28b-offer-rare-disease-drugmaker-sanofi-exits-bidding-war">Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war</a> </li>
<li><a href="https://www.fiercepharma.com/pharma/sanofi-started-and-lost-28b-bidding-war-horizon-companys-ma-appetite-still-rumbling">Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&amp;A appetite still rumbling?</a> </li>
<li><a href="https://www.fiercepharma.com/marketing/biogen-daiichi-sankyo-ucb-lundbeck-astrazeneca-all-hit-drug-marketing-breaches-highest">AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk</a></li>
</ul>
"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement